Baudax Bio Reports First Quarter Financial Results and Provides Business Update
Table 1 FDA Required Primary Efficacy Endpoint Figure 2 Study BDX-22-006 Primary Endpoint Figure 3…
Table 1 FDA Required Primary Efficacy Endpoint Figure 2 Study BDX-22-006 Primary Endpoint Figure 3…
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE…
LONDON, May 12, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) (the Company,…
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time YAVNE,…
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022…
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a provider…
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels…
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company…
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris…
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left…
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of…
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned…
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets…
Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include…